SBIR/STTR Research Award

Antimicrobial Photodynamic Wound Dressings

Award identifier 705e7c1d84a62e3f775e2f5aef4057aa83d6bc008df515a038e7a65955bb0585Awarding agency Department of Defense · Army

Award amount

$171,836

Program and phase

STTR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Army
Recipient company
PHOTOCIDE PROTECTION INC
Proposal award date
2022-06-29
Contract end date
2023-01-11
UEI
CV3RHJ1J52E4
Solicitation number
21.C
Topic code
A21C-T010

Research abstract

Bacterial infections from combat injuries present a significant threat to Warfighters, particularly in the 30 hours immediately after a traumatic injury where there may be a long delay before treatment at a field hospital or clinic. Acute infections stemming from the time of injury can turn into chronic ones, with significant negative impacts on patient recovery. Aside from acute trauma in far-forward situations, patients later face the threat of healthcare-acquired infections (HAIs affect about 5% of all hospital patients in the U.S.). Increasingly HAIs are caused by drug-resistant bacteria that defy standard treatment options. Current combat wound care often includes bandages impregnated with antimicrobial agents, such as nano-silver or antimicrobial polymers, which can reduce antimicrobial growth in wounds, but not fully eliminate it. PhotoCide Protection is developing wound dressings based on light-activated production of reactive oxygen species that rapidly inactivate a broad range of pathogens. This technology, termed antimicrobial photodynamic inactivation, produces highly microbicidal singlet oxygen upon visible light illumination that causes non-specific damage to bacteria and other pathogens. A related application, photodynamic therapy, has been FDA-approved for the treatment of certain cancers. In this project we will evaluate different formulations of antimicrobial coatings on bandages for efficacy in vitro, and in an ex vivo pig skin wound model. PhotoCide has already established methods for the production of antimicrobial photodynamic wound dressings at a TRL of 8-9. For deep tissue wounds, we will also develop a self-contained illumination system that turns on automatically when the bandages are deployed. In this Phase I STTR, we anticipate developing the proof-of-concept for this self-illuminating wound dressing kit to an overall TRL of 3. In Phase II, we expect to develop field-tested prototypes with a TRL of 8-9, and identify opportunities for large scale production.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2020–2022). Reported award amounts total $396,836. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Defense, National Science Foundation

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.